title: Uterine sarcoma: a clinicopathological study of 93 cases.
abstract: OBJECTIVE
  To evaluate the clinical outcome of patients suffering from primary uterine sarcoma diagnosed and treated in our Hospital.
  
  
  METHODS
  Department of Gynecologic Surgery/Gynecologic Oncology, Hospital Universitario Materno-Infantil Vall d'Hebron de Barcelona, Barcelona, Spain.
  
  
  METHODS
  A retrospective review from 1967 to 1995 of clinical and pathological characteristics of 93 patients with primary uterine sarcoma was done. Patients were staged using the 1988 FIGO histological classification for uterine cancer. Clinical features, type of surgery, adjuvant therapy, recurrences, distant metastasis, and survival were recorded.
  
  
  RESULTS
  Our study included three main histologic types: 44 patients with leiomyosarcoma, 26 patients with endometrial stromal sarcoma, and 18 patients with mixed Müllerian sarcomas. The mean age for all patients was 54.8 years, and the most common symptom was vaginal bleeding. Other clinicopathological features were examined. Although surgery was the most frequent treatment, adjuvant therapies have been analyzed and discussed. The overall three-year survival rate was 67.9% and the overall five-year survival rate was 64.5%. We found statistical differences (p < 0.001) between the stage I survival rate and other stage survival rates.
  
  
  CONCLUSIONS
  Uterine sarcoma is an uncommon neoplasia diagnosed in the 6th decade of life. Leiomyosarcoma is the most frequent histologic type (47.3%). Stage I uterine sarcoma has a better prognosis than other stages.
authors.affiliation: Department of Gynecologic Surgery/Gynecologic Oncology, Hospital Universitario Materno-Infantil Vall d'Hebron, Barcelona, Spain.
authors.forename: E
authors.initials: E
authors.lastname: González-Bosquet
authors.forename: J M
authors.initials: JM
authors.lastname: Martínez-Palones
authors.forename: J
authors.initials: J
authors.lastname: González-Bosquet
authors.forename: A
authors.initials: A
authors.lastname: García Jiménez
authors.forename: J
authors.initials: J
authors.lastname: Xercavins
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008875:Middle Aged; D018199:Mixed Tumor, Mesodermal / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D018203:Sarcoma, Endometrial Stromal / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy